Cara's Story

Aug 22, 2023

If the universal saying for being optimistic is having a glass half full, then Cara Campbell’s glass is overflowing. Even as a single mom raising two children in her early 20s, Cara always kept her mind on the positive things and didn’t dwell on the negatives. Raised by a supportive family, she brought up her children the same way. Cara taught them that no matter what happens in life, always be thankful for what you have. 


But Cara had no idea that the same life lesson she was teaching her kids would test her when it showed up in the form of breast cancer. 


At age 29, Cara woke up with her hand on her chest, an unusual thing for her. She felt a small lump on her breast but didn’t think anything of it and went back to sleep. When she woke up the following morning, she remembered feeling the lump and realized it was still there. “It wasn’t a dream; it was definitely something I’d never felt before,” she says. 

"Everything happened really fast."

Cara made sure to visit her doctor right away for a thorough breast exam. The doctor told her the lump was likely a cyst, not cancer, but to schedule a mammogram just to be sure. “I booked a mammogram on my way to work, thinking I’m going in as a precaution,” she says. 


At the appointment, Cara was brought back into the exam room for an unexpected ultrasound following the mammogram. Then, she was told she’d also need a biopsy. “At this point, I was sort of starting to freak out,” she says.


Roughly two weeks after feeling the lump on her breast for the first time, Cara was diagnosed with breast cancer. She’d later find out that it was HER2-positive breast cancer, a type that tends to grow and spread more aggressively than HER2-negative breast cancers. “Everything happened really fast,” says Cara. Three weeks post-diagnosis, she had the lump and her lymph nodes removed. 


Over the course of a year, Cara underwent many more surgeries and treatments to ensure her cancer was completely removed. These included a mastectomy, reconstructive breast surgery, six breast cancer-specific treatments of chemotherapy, 30 treatments of radiation, a skin graft surgery to reform her thinned breast tissue after prolonged radiation, a final breast augmentation surgery and 17 treatments of chemotherapy specifically to treat HER2-positive cancer. 


During treatment, Cara met many other young women going through the same thing. “When I was growing up, if you got breast cancer at 50, that was young. It feels more prevalent in younger women now. It’s not an older person's disease,” she says. In fact, in North America, women under 50 represent 18 percent of breast cancer diagnoses. 


Connecting with other women helped Cara navigate some of the fear and uncertainty, but her optimism and family life kept her afloat through it all. “I needed to show my kids that life can deal you some terrible stuff, but to find positive moments and persevere,” she says. “My son was almost four and my daughter was only seven when I was diagnosed. In my head, dying wasn’t an option.”

Throughout treatment, Cara never missed any of her kids’ extracurricular activities and made a point of participating in cancer awareness events with her support system of friends and family. Together, Cara and her loved ones acknowledged both challenges and triumphs. They even had parties to mark milestones, like her last chemotherapy treatment. 


Another celebration came from a particularly challenging moment for Cara – shaving her head. “Losing my hair was scarier than losing my breast,” she says. Turning it into a head-shaving party made the process a lot less scary. Her children were involved too, with her daughter taking a few snips with the scissors. Being surrounded by love and support makes you realize that hair doesn’t change beauty, Cara says. “I’ve never felt more beautiful than I did on that day.”

Although Cara has been cancer free for over a decade, she remains an advocate for early detection and an inspiration for young women like her daughter, who’s now in her 20s. “I’ve always shared my story,” says Cara. “I never wanted cancer to be my identity, just something that I went through. And I’d love to help anyone else that’s going through it too.”

Syantra press release graphic dated November 14, 2023
14 Nov, 2023
Syantra announces additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease.
01 Nov, 2023
CALGARY, AB. - Today, Syantra, a liquid biopsy platform and innovation company that is changing the way cancer is detected, starting with Syantra DX™ Breast Cancer , announced that Rob Lozuk has been appointed as Chief Executive Officer, effective November 1, 2023. “Rob brings over 23 years of experience successfully scaling and transacting commercially disruptive technologies across the healthcare landscape,” said Kristina Rinker, PhD, Chief Scientific Officer and Co-founder of Syantra. “We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection. Rob will bring substantial value to our organization as we expand into the United States with commercial introduction of the Syantra DX™ Breast Cancer test, a blood test that identifies individuals who may have breast cancer, including early-stage disease.” “The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable. Entirely too many early-stage cancers are still being missed, at a time when the opportunity for intervention and survival is the greatest. Truly disruptive healthcare technologies are generational – and that’s exactly what Syantra’s liquid biopsy platform will become” states CEO of Syantra, Rob Lozuk, and adds, “I’m thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena. Our AI-powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body’s immune response that allows cancer to develop. We will rapidly expand the clinical data of the Syantra DX™ Breast Cancer blood test over the remainder of 2023 in preparation for broad global commercialization in 2024.” Within the precision biotech space, Syantra’s liquid biopsy platform has already demonstrated impressive performance statistics as exemplified in the Analytical and Clinical Performance from the Early Analysis of the International Identify Breast Cancer (IDBC) Study, presented by Professor Nigel Bundred, Surgical Oncologist with the Manchester University NHS Foundation Trust, Wythenshawe Hospital, at the 13th European Breast Cancer Conference in Barcelona, Spain, in November of 2022. About Rob Lozuk Prior to joining Syantra, Rob was the Chief Business Officer at Cardea Bio, which culminated in a sale to Paragraf in 2023. Rob was also the President of Specific Diagnostics, which was sold to bioMérieux in 2022. As a public company officer, Rob led the global commercial and operating businesses at Sequenom, a pioneer in revolutionizing the prenatal space, which was successfully transacted to Lab Corp (LH). Prior to Sequenom, Rob was the P&L leader for ThermoFisher Scientific’s Advanced Staining Business and served as Director of Sales, Marketing and Business Development. About Syantra, Inc. Syantra is a precision biotechnology company changing the way cancer is detected and treated with revolutionary high-performance blood-based tests providing a new way to help detect cancer. Syantra’s scalable, patent-protected platform is based on changes in the immune system and other systemic factors that occur when a cancer tumor is present. These changes can be measured through mRNA biomarkers that are contained in a small amount (2.5ml) of blood. When biomarker expression is combined with patient characteristics, there is a high correlation to the presence or absence of disease. The Syantra platform includes a custom real-time PCR process with proprietary software that includes machine learning-based algorithms. Syantra’s blood testing platform provides a cost-effective way to help identify individuals who may have cancer and should be further evaluated. About the Syantra DX™ Breast Cancer test Syantra is changing the way cancer is detected and treated. Its flagship product, Syantra DX™ Breast Cancer , is a minimally invasive and high-performance blood test for the detection of breast cancer signals at the earliest stages, when breast cancer is easier to treat. The Syantra DX™ Breast Cancer test will be available to women in Canada and the United States in early 2024.
Katie Smith-Parent, stage two hormone-positive breast cancer survivor,  smiles in her kitchen.
25 May, 2023
In her early 30s, Katie Smith-Parent noticed a lump on her breast. She was initially told by a doctor not to worry and that the lump would go away on its own. She trusted her instincts and after finding a new doctor, she was diagnosed with stage two hormone-positive breast cancer. Today, she is an advocate for early detection and oncofertility.
Syantra Press Release graphic dated April 18, 2023
18 Apr, 2023
Syantra announced today that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat. Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.
Olesya Kharenko stands in front of Syantra lab in lab coat.
08 Feb, 2023
The typical career journey for a scientist is fairly linear. But a lens focused on only one speciality can make it challenging to leverage the many ways these disciplines can crossover. Imagine the possibilities of a single scientist who brings expertise from more than three disciplines to research. Syantra found that in Olesya Kharenko, PhD.
Syantra press release dated January 18, 2023 announcing promotion of Carol Roesler to VP
16 Jan, 2023
Syantra Inc. announced today the promotion of Carol Roesler to Vice President, effective January 2023. Carol will maintain her current responsibilities in her new role, in addition to supporting Canadian business development for the Syantra DX™ Breast Cancer test.
Syantra DX Breast Cancer requisition with blood test tube
08 Nov, 2022
Syantra will present findings from the IDBC Study at the 13th European Breast Cancer Conference, held in Barcelona, Spain from 16 -18 November 2022.
Syantra press release dated October 27, 2022 announcing appointment of Dr. Massimo Cristofanilli
27 Oct, 2022
Syantra appoints Dr. Massimo Cristofanilli, a world-renowned leader in the field of breast cancer, to its Scientific Advisory Board (SAB) effective Sept 1, 2022. Dr. Cristofanilli is a Professor of Medicine, Chief of Breast Medical Oncology and Associate Director of Precision Medicine at Weill-Cornell Medicine.
Jesslyn Davies, a 33-year-old woman battling breast cancer, smiling in her Calgary home
18 Oct, 2022
In November 2020, Jesslyn Davies, a 33-year-old registered nurse and mother of two young boys, noticed a small cyst on her breast. Soon after, she was diagnosed with Triple Negative Stage 2B breast cancer.
Matalyn Schall poses with Syantra team wearing white lab coats at Syantra lab.
06 Oct, 2022
Since winning Miss Junior Teen Calgary pageant in April 2022, Matalyn Schall has been raising awareness of the importance of early breast cancer detection. That's when she found Syantra, a precision health care company that can detect breast cancer in the blood even at the earliest stages.
More Posts
Share by: